Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Liabilities (2016 - 2025)

Coherus Oncology's Other Non-Current Liabilities history spans 13 years, with the latest figure at $102000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $102000.0; the TTM value through Sep 2025 reached $102000.0, changed N/A, while the annual FY2024 figure was $29.3 million, 185.11% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $102000.0 at Coherus Oncology, down from $16.7 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $29.3 million in Q4 2024 and bottomed at $102000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Liabilities is $691000.0 (2021), against an average of $4.0 million.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 86.42% in 2022 before it soared 9985.29% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $750000.0 in 2021, then plummeted by 86.4% to $102000.0 in 2022, then skyrocketed by 9985.29% to $10.3 million in 2023, then soared by 185.11% to $29.3 million in 2024, then crashed by 99.65% to $102000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Non-Current Liabilities are $102000.0 (Q3 2025), $16.7 million (Q2 2025), and $29.3 million (Q4 2024).